Zim Laboratories Complete Financial Statements
In FY2026, Zim Laboratories (ZIMLAB) reported revenue ₹111 Cr, net profit ₹4 Cr and EPS ₹0.76, with a net profit margin of 3.6% and ROE of 1.7%. Full financial statements from FY2015 to FY2026 (12 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. Explore ZIMLAB intrinsic value to estimate fundamental worth using multiple valuation models.
Complete Financial Data Export
Profitability Ratios
Balance Sheet Ratios
ZIMLAB Revenue, Net Profit & EBITDA — Year-on-Year Growth
ZIMLAB YoY (Mar 2025 vs Mar 2026) — revenue +0.9%, net profit -20.0%, EBITDA -18.8%, expenses +4.3%. For live price, earnings ratios and company overview, see Zim Laboratories share price chart.
ZIMLAB Income Statement — Revenue, EBITDA & Net Profit
Zim Laboratories revenue ₹111 Cr, EBITDA ₹13 Cr, net profit ₹4 Cr, EPS ₹0.76 (2026) — net profit margin 3.6%. Review Zim Laboratories price earnings to evaluate earnings-based valuation against sector peers.
| Particulars | Mar 2026 | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | Sept 2024 | Mar 2024 | Jun 2024 | Dec 2024 | Sept 2023 | Mar 2023 | Jun 2023 | Dec 2023 | Sept 2022 | Mar 2022 | Jun 2022 | Dec 2022 | Sept 2021 | Mar 2021 | Jun 2021 | Dec 2021 | Sept 2020 | Mar 2020 | Jun 2020 | Dec 2020 | Sept 2019 | Mar 2019 | Jun 2019 | Dec 2019 | Sept 2018 | Mar 2018 | Jun 2018 | Dec 2018 | Sept 2017 | Jun 2017 | Dec 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 111 | 91 | 110 | 73 | 110 | 94 | 119 | 83 | 98 | 87 | 106 | 69 | 97 | 101 | 107 | 95 | 103 | 78 | 75 | 65 | 87 | 88 | 72 | 71 | 76 | 68 | 95 | 69 | 74 | 72 | 79 | 71 | 99 | 64 | 64 | 75 |
| Expenses | 98 | 83 | 94 | 68 | 96 | 83 | 102 | 74 | 85 | 77 | 90 | 63 | 85 | 87 | 90 | 82 | 88 | 67 | 65 | 59 | 76 | 81 | 62 | 60 | 67 | 63 | 84 | 64 | 65 | 61 | 62 | 62 | 85 | 55 | 57 | 64 |
| EBITDA | 13 | 8 | 16 | 6 | 15 | 11 | 17 | 9 | 13 | 11 | 16 | 6 | 13 | 14 | 16 | 13 | 16 | 11 | 10 | 7 | 11 | 8 | 9 | 11 | 8 | 5 | 11 | 4 | 9 | 11 | 17 | 9 | 13 | 9 | 7 | 11 |
| Operating Profit Margin % | 7.00% | 6.00% | 13.00% | 6.00% | 12.00% | 10.00% | 13.00% | 10.00% | 12.00% | 11.00% | 15.00% | 7.00% | 12.00% | 12.00% | 14.00% | 12.00% | 13.00% | 13.00% | 12.00% | 8.00% | 12.00% | 9.00% | 10.00% | 15.00% | 10.00% | 7.00% | 11.00% | 5.00% | 11.00% | 14.00% | 13.00% | 12.00% | 13.00% | 13.00% | 11.00% | 15.00% |
| Depreciation | 5 | 5 | 5 | 5 | 5 | 5 | 4 | 5 | 5 | 4 | 5 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 3 | 3 | 4 | 3 | 3 | 3 | 3 | 2 | 2 | 3 |
| Interest | 3 | 3 | 3 | 3 | 3 | 3 | 2 | 3 | 3 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 2 | 3 | 3 | 3 | 2 | 3 | 3 | 3 | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 2 | 2 |
| Profit Before Tax | 5 | 0 | 8 | -2 | 6 | 3 | 11 | 1 | 6 | 5 | 10 | 0 | 7 | 8 | 11 | 8 | 10 | 4 | 3 | 0 | 6 | 1 | 3 | 4 | 2 | -2 | 5 | -2 | 2 | 5 | 11 | 4 | 8 | 4 | 3 | 7 |
| Tax | 1 | 0 | 3 | -1 | 2 | 1 | 3 | 0 | 2 | 1 | 3 | 0 | 2 | 3 | 4 | 2 | 3 | 1 | 1 | 0 | 2 | 0 | 0 | 1 | 1 | -1 | 3 | -3 | 0 | 1 | 3 | 0 | 2 | 1 | 1 | 1 |
| Net Profit | 4 | 0 | 5 | -2 | 4 | 2 | 8 | 1 | 4 | 4 | 7 | 0 | 5 | 5 | 7 | 5 | 7 | 3 | 2 | 0 | 4 | 1 | 2 | 3 | 1 | -1 | 2 | 0 | 2 | 3 | 8 | 4 | 6 | 3 | 2 | 6 |
| Earnings Per Share (₹) | 0.76 | -0.09 | 1.01 | -0.38 | 0.90 | 0.49 | 1.66 | 0.18 | 0.82 | 0.85 | 1.48 | 0.05 | 0.98 | 3.35 | 4.33 | 3.17 | 1.35 | 2.00 | 0.95 | 0.12 | 2.51 | 0.73 | 1.41 | 2.02 | 0.80 | -0.37 | 1.43 | 0.05 | 0.94 | 2.08 | 4.84 | 2.35 | 3.65 | 1.79 | 2.66 | 7.81 |
ZIMLAB Balance Sheet — Assets, Liabilities & Shareholders' Equity
ZIMLAB total assets ₹0 Cr, total equity ₹0 Cr, total liabilities ₹ Cr (2026) — ROE 1.7%.
| Particulars | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| Total Assets | 0 | 0 | 447 | 342 | 342 | 325 | 325 | 329 | 298 | 259 | 256 | 265 |
| Current Assets | 0 | 0 | 228 | 191 | 212 | 192 | 182 | 194 | 173 | 154 | 154 | 168 |
| Fixed Assets | 0 | 0 | 161 | 109 | 106 | 107 | 116 | 106 | 94 | 89 | 92 | 87 |
| Capital Work in Progress | 0 | 0 | 42 | 27 | 12 | 11 | 10 | 13 | 8 | 4 | 3 | 6 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 0 | 0 | 244 | 206 | 224 | 208 | 200 | 209 | 196 | 166 | 161 | 172 |
| LIABILITIES | ||||||||||||
| Total Liabilities | ||||||||||||
| Current Liabilities | 0 | 0 | 49 | 30 | 20 | 22 | 28 | 22 | 20 | 28 | 35 | 38 |
| Non-Current Liabilities | ||||||||||||
| SHAREHOLDERS' EQUITY | ||||||||||||
| Total Equity | 0 | 0 | 239 | 200 | 176 | 161 | 154 | 151 | 137 | 118 | 99 | 94 |
| Share Capital | 0 | 0 | 49 | 49 | 16 | 16 | 16 | 16 | 8 | 8 | 8 | 8 |
| Reserves & Surplus | 0 | 0 | 190 | 152 | 160 | 145 | 138 | 135 | 129 | 110 | 91 | 86 |
ZIMLAB Cash Flow Statement — Operating, Investing & Financing
Zim Laboratories operating cash flow ₹50 Cr, investing ₹-55 Cr, financing ₹28 Cr, net cash flow ₹23 Cr (2026).
| Particulars | March 2026 | March 2025 | March 2024 | March 2023 | March 2022 | March 2021 | March 2020 | March 2019 | March 2018 | March 2017 | March 2016 | March 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 50 | 41 | 16 | 38 | 49 | 32 | 22 | 35 | 37 | 32 | 22 | 6 |
| Investing Activities | -55 | -40 | -73 | -36 | -14 | -6 | -19 | -21 | -26 | -7 | -12 | -9 |
| Financing Activities | 28 | -9 | 60 | 1 | -33 | -26 | -2 | -15 | -10 | -25 | -10 | -4 |
| Net Cash Flow | 23 | -8 | 3 | 3 | 2 | 0 | 1 | -1 | 1 | 0 | 0 | -7 |